Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 24, 2025 08:30 ET | Source: Er-Kim Pharmaceuticals

Er-Kim Enters Commercialization Agreement with Sentynl Therapeutics for Nulibry® (fosdenopterin) and Zokinvy® (lonafarnib), Targeting Ultra-Rare Diseases

Distribution agreement expands access of Nulibry and Zokinvy to 33 countries within CEE, the Mediterranean, and Eurasia